Halozyme Therapeutics, Inc. HALO

NASDAQ | Biotech | Biotechnology and drug delivery

General analysis — not personal advice.

Signal
BUY
Market sentiment
Positive

Strong Q1 execution, reiterated 2026 guidance, and a sizable buyback program improve the near-term return profile and can support EPS/share price, while multiple partner-driven catalysts broaden the future royalty base.

Follow Halozyme Therapeutics free Follow free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Updated: 12 May 2026
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology and drug delivery

Market sentiment

Sentiment has improved following an earnings beat and a larger-than-expected buyback program; overall newsflow is positive and focused on royalty growth and an expanding partner catalyst set.

Why this signal

Strong Q1 execution, reiterated 2026 guidance, and a sizable buyback program improve the near-term return profile and can support EPS/share price, while multiple partner-driven catalysts broaden the future royalty base.

  • Consider adding incrementally (e.g., 2–3 tranches) given buyback support and upcoming partner/pipeline events, while staying prepared for partner-news-driven volatility.

We're already tracking Halozyme Therapeutics, Inc. — here are the latest events we've registered

Recent News

  • On August 6, 2026, Halozyme reported record second-quarter 2026 financial results, with total revenues increasing 48% year-over-year to $481 million. The growth was driven by a 50% surge in royalty revenue from ENHANZE-enabled partner products such as DARZALEX SC and VYVGART Hytrulo. Following the strong quarter, the company raised its full-year 2026 financial guidance for total revenue, royalties, and adjusted EBITDA.

Catalysts

31 Dec 2026 — Share repurchases: at least $400M during 2026

Dilution Risk

Assessment: Low

What Firelda Watch includes for Halozyme Therapeutics, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Halozyme Therapeutics, Inc. will be delivered in the same format.
Follow Halozyme Therapeutics free Follow free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Halozyme Therapeutics, Inc. HALO
Halozyme Therapeutics — this picture changes. Follow free
Follow Halozyme Therapeutics free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.